029 Group SE

Earnings Release • Apr 5, 2005

News Details

Ad-hoc | 5 April 2005 08:14

Rhein Biotech N.V. reports 2004 full year results

Ad hoc announcement §15 WpHG Full year results 2004 Rhein Biotech N.V. reports 2004 full year results Ad hoc announcement transmitted by DGAP. The issuer is solely responsible for the content of this announcement. —————————————————————————— Rhein Biotech N.V. reports for the Full Year 2004 net sales of 44.2 million Euro. The EBITDA was 3.6 million Euro, while the loss from operations (EBIT) was – 6.3 million Euro. Rhein Biotech’s net loss in 2004 was -8.4 million Euro. The company’s cash position at the end of December 2004 was 15.5 million Euro. Consolidated income statement for the year ending December 31, 2004 (Dutch GAAP): Amounts in EUR ‘000, 2004 Net sales: 44’236 Loss from operations (EBIT): -6’389 Financial result, net: -1’173 Other operating income: 558 Loss before taxes: -7’004 Taxes: -1’220 Impairment of not consolidated companies: -106 Minority interests: -35 Consolidated net loss: -8’365 Income from operations before depreciation (EBITDA): 3’606 Rhein Biotech N.V. Gaetano Martinolaan 95 6229 GS Maastricht Netherlands ISIN: NL0000230324 WKN: 919544 Listed: Geregelter Markt in Frankfurt (General Standard); Freiverkehr in Berlin-Bremen, Düsseldorf, Hamburg, Hannover, München und Stuttgart End of ad hoc announcement (c)DGAP 05.04.2005 050814 Apr 05